Clinical Study on Xuesaitong Soft Capsule for Patients with Unstable Angina Pectoris: a Randomized Controlled Trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000032152

Enrollment

Unknown

Registered

2020-04-21

Start date

2020-05-11

Completion date

Unknown

Last updated

2020-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

unstable angina pectoris

Interventions

experimental group: Xuesaitong Soft Capsule

control group:placebo

Eligibility

Sex/Gender

All

Age

40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 40-75 years, male or female; 2. Patients who meet the diagnosis of unstable angina pectoris and undergo coronary intervention.

Exclusion criteria

Exclusion criteria: Those who meet any of the following are excluded: 1. Those with hypertension who still have high blood pressure after treatment with antihypertensive drugs (systolic blood pressure >= 180mmHg, diastolic blood pressure >= 100mmHg); 2. Severe arrhythmia (atrial fibrillation with rapid ventricular response, atrial flutter, paroxysmal ventricular tachycardia, etc.); 3. Pulmonary heart disease, rheumatic heart disease, myocarditis, cardiomyopathy, aortic dissection, pulmonary embolism; 4. Gastrointestinal ulcer; 5. History of infection, fever, trauma, burns, and surgery within the past month; 6. Acute myocardial infarction or acute stroke in the past month; 7. Active rheumatoid immune disease; 8. Active tuberculosis; 9. Those whose serum alanine aminotransferase or serum creatinine is > 2 times the upper limit of the normal reference value; 10. People with severe hematological diseases; 11. Malignant tumors; 12. Pregnant women, lactating women, or women of childbearing age with childbearing requirements; 13. People with mental illness or cognitive impairment; 14. Those who are allergic to the test drug; 15. Participants in other clinical trials in the last 1 month; 16. Those who refuse to sign the informed consent.

Design outcomes

Primary

Measure	Time frame
Hs-CRP;	—

Secondary

Measure	Time frame
tumor necrosis factor-a;interleukin-6;von Willebrand Factor;platelet aggregation rate;endothelin-1;Nitric Oxide;Routine blood test;Urine routine;stool routine;liver function;	—

Countries

China

Contacts

Public ContactDazhuo Shi

Xiyuan Hospital of China Academy of Traditional Chinese Medicine

lsycardio@163.com+86 010 62835392

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026